VSIR and prostate carcinoma: Gao et al. have demonstrated PD-L1 and VISTA expression on predominantly distinct subsets of CD68+ Mφs representing individual subsets of inhibitory cells in tumor tissues from prostate cancer patients who underwent checkpoint immunotherapy [30].